RESEARCH TRIANGLE PARK – T3D Therapeutics, a life science startup seeking to develop a treatment for Alzheimer’s disease, has another $740,000 to use in pursuit of its research courtesy of the Alzheimer’s Association and its partner Bill Gates.
“It is an honor to have won this highly competitive award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program and the recognition that improving inherent metabolic defects in Alzheimer’s disease is a vital and largely unexplored therapeutic avenue to treat AD” said Chief Executive Officer John Didsbury in the announcement made Thursday.
The compound T3D-959 is an orally administered therapy that is nearing a Phase 2 clinical study.
The grant will be used in part to fund the trial.
Gates works with the association through a “Part the Cloud” partnership.
Original Article Source: WRAL TechWire